AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05157763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EscharEx 5% (EX-02 formulation)
Description: EX-02 5% will be topically applied in a thick layer of 2-3 mm on the lesion surface for 8-12 hours including 5-10 mm margins and covered with an occlusive dressing. A new vial should be used for each application. Each patient will be treated with 7 applications.
Study NCT04948632 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complete LeoMed application
Description: Access to the complete LeoMed application on the participant's smartphone. The day before surgery, participants will receive notifications encouraging them to use the platform to help prepare for their surgery. Safety instructions will also be sent. Postoperatively, notifications will be sent to the participants every day during the first 4 days and on the 7th day. These notifications will direct them to online forms that aim to assess their condition. On the 15th and 30th postoperative day, the platform will send a follow-up form. The platform will collect this information and classify it for appropriate management of their condition.
Study NCT04948632 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Basic LeoMed application
Description: Access to a partial version of the LeoMed application on the patient's smartphone during a visit to the preoperative clinic. Before surgery, participants will receive a phone call to be summoned to the hospital and to remind them of the safety instructions. Postoperatively, their follow-up will not be standardized and will vary depending on their surgeon. On the 15th and 30th postoperative day, the platform will send a follow-up form. In the event of an emergency, they will receive the contact details of the CHUM Health Infoline to ensure the continuity of their care.
Study NCT05877664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZG0895 Hydrochloride for Injection
Description: The dose escalation of ZG0895.HCl is set as 0.06, 0.12, 0.18, 0.37, 0.75, 1.50, 2.25, 3.00, and 3.75 mg/m\^2 groups, subcutaneous (SC) injection once a week (QW)
Study NCT05186298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ PanOptix®
Description: The AcrySof IQ PanOptix® (Alcon) mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL
Study NCT05186298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synergy®
Description: The TECNIS Synergy™ IOLs mitigate the effects of presbyopia by providing far vision comparable to an aspheric monofocal IOL. Compared to an aspheric monofocal IOL, the lens provides significantly improved intermediate and near vision, including in low-light conditions.
Study NCT05186298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: IOL implantation will be performed
Study NCT05077449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3287+Fulvestrant
Description: XZP-3287 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
Study NCT05130021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-40279-01
Description: MAX-40279-01 50mg/70mg
Study NCT05130021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: regorafenib
Study NCT05051085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered treatment: SpilleFri.
Description: The guided internet program consists of 8 modules over a period of 10 weeks. The content is written psychoeducation, videos with patients and experts, and exercises (encouraging reflection, cognitive restructuring, and exposure). The program is therapist-guided; hence all patients will receive support primarily from a specific therapist during the 10 weeks.
Study NCT05328843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB119
Description: Each subject received only one dose of study drug during the study period. After completing the pre-dose procedure on the morning of the first day of the study, the subjects were given a subcutaneous injection of PB-119 0.3 mL (150 μg) once in the abdomen by the study nurse. The actual time of administration will be recorded in the subject's eCRF.~Subjects should remain on an empty stomach for at least 10 hours prior to administration.
Study NCT05516095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnet stimulation
Description: Theta burst stimulation, which is a form of Transcranial magnet stimulation, works by inducing focused magnetic field pulses to make durable changes in the activity of brain regions. The magnetic pulses are transferred to the brain through an electromagnetic coil.
Study NCT05516095 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Transcranial magnet stimulation
Description: Similar in appearance and give the same sound as the active device, but deliver no magnetic pulse that reach the brain
Study NCT06295146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention A: 1-on-1 wheelchair skills training by a peer coach
Description: Trainees will engage in 1:1 virtual zoom meetings facilitated by the study team scheduled weekly for 6 sessions with the opportunity for 2 makeup sessions. Sessions will last approximately 30 minutes and may include goal setting, review of progress, instruction, and homework of prescribed content for trainees to review. Participants may upload videos of themselves completing skills through Qualtrics to get feedback.
Study NCT06295146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention A: 1-on-1 wheelchair skills training by a peer coach
Description: Trainees will engage in 1:1 virtual zoom meetings facilitated by the study team scheduled weekly for 6 sessions with the opportunity for 2 makeup sessions. Sessions will last approximately 30 minutes and may include goal setting, review of progress, instruction, and homework of prescribed content for trainees to review. Participants may upload videos of themselves completing skills through Qualtrics to get feedback.
Study NCT06295146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention B: Training via educational videos
Description: Intervention B will be a series of educational videos that participants review and then are encouraged to the practice the skills. Participants will have access to the materials for 8 weeks. Group 3 will have access to approximately 3 hours of wheelchair skills video training content. Actual viewing time will depend upon the individual's training goal. While they will receive a weekly reminder about practicing, there is no prescribed frequency for how often they should be practicing the skills in the videos.
Study NCT06380530 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deformity correction
Description: Surgeries to correct bone defomity, supported by the use of preoperative planning and/or patient-specific instruments
Study NCT04745988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib 20mg
Description: Lenvatinib will be administered at a dose of 20mg as oral dose, once a day.
Study NCT04745988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at a dose of 200mg as a 30-minutes IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
Study NCT04745988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib 8mg
Description: Lenvatinib will be administered at a dose of 8mg as oral dose, once a day.
Study NCT04745988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered at a dose of 50mg/m\^2 as a IV infusion, Q2W.
Study NCT04745988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered at a dose of 85mg/m\^2 as a IV infusion, Q2W.
Study NCT04745988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofolinate
Description: Levofolinate will be administered at a dose of 200mg/m\^2 as a IV infusion, Q2W.
Study NCT04745988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Levofolinate will be administered at a dose of 2600mg/m\^2 as a IV infusion, Q2W.
Study NCT06150014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TQA3605 placebo tablets were orally administered on an empty stomach (at least 2 hours before or after meals) with warm.
Study NCT06150014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQA3605 tablets
Description: TQA3605 inhibits viral replication.
Study NCT06150014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir dispersible tablets
Description: Entecavir inhibits viral replication and indicated for chronic hepatitis B treatment.
Study NCT06150014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir dispersible tablets
Description: Entecavir inhibits viral replication and indicated for chronic hepatitis B treatment.
Study NCT06150014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate tablet
Description: Tenofovir disoproxil fumarate is a Nucleotide reverse transcriptase inhibitor.
Study NCT06150014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir disoproxil fumarate tablet
Description: Tenofovir disoproxil fumarate is a Nucleotide reverse transcriptase inhibitor.
Study NCT06150014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir alafenamide fumarate tablet
Description: Tenofovir alafenamide fumarate inhibits hepatitis B virus replication.
Study NCT06270290 — intervention group
Intervention type: OTHER
Intervention: Exposure to contact sports or history of concussions
Description: History of contact sports practices or of concussions
Study NCT04797286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil 20 mg three times a day. This is the approved dose for the treatment of pulmonary arterial hypertension. It is being studied in this trial with a population who has mildly elevated pulmonary pressures.
Study NCT04797286 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral pill placebo.
Study NCT06150014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir alafenamide fumarate tablet
Description: Tenofovir alafenamide fumarate inhibits hepatitis B virus replication.
Study NCT06557577 — intervention group
Intervention type: OTHER
Intervention: No intervention group.
Description: There is no intervention group.
Study NCT05995366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903
Description: Solution; Oral
Study NCT04919343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BBC Education Tiny Happy People videos
Description: This intervention involves regular texting of BBC Education Tiny Happy People videos to parents
Study NCT04919343 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical health control intervention
Description: This intervention involves regular texting of publicly available videos about supporting infant physical and dental health to parents
Study NCT04617223 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic sinus evacuation
Description: Evacuation of the sinus by using endoscope
Study NCT04724200 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Echocardiography plays a crucial role in the diagnosis of HF; it is the standard of care imaging modality used to confirm the diagnosis, it permits real-time imaging of the heart and quantitative assessment of cardiac structure and function, crucial for diagnosis.
Study NCT06129682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self rehabilitation at home
Description: 6 week program of exercise at home of gradual intensity and duration
Study NCT06197516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Neuromuscular Inhibition Technique
Description: After palpating the trigger point ischemic compression were applied for 20-60 sec while strain Counterstain for 60-90 sec and MET is for 7-10 sec.
Study NCT06197516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Reeducation Technique
Description: Deep pressure were applied along origin and insertion of Piriformis and hamstring muscle combined with active movement of patient for 5 -15 time as per required
Study NCT03547232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin SR
Description: Indomethacin SR 50mg given q12h from admission day 1 to day 7
Study NCT03547232 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebos
Description: Similar shape and size suppositories (Placebos) without indomethacin given q12h from admission day 1 to day 7
Study NCT06131593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAPB with dexamethasone as an adjuvant to local anesthetics
Description: patients will receive TAPB with dexamethasone as an adjuvant to bupivacaine and lidocaine local anesthetics
Study NCT06131593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAPB with methylprednisolone as an adjuvant to local anesthetics
Description: patients will receive TAPB with methylprednisolone as an adjuvant to bupivacaine and lidocaine local anesthetics
Study NCT06340594 — intervention group
Intervention type: PROCEDURE
Intervention: Laproscopic cholecystectomy (LC)
Description: Removal of gallbladder via laparoscopy
Study NCT06340594 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic Retrograde Cholangiopancreatography (ERCP)
Description: Removal of bile duct stones via endoscopy
Study NCT06449261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manual therapy used in Physiotherapy Practice
Description: C5-C6 and thoracic spine mobilization with postural correction
Study NCT06449261 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Manual therapy used in Physiotherapy Practice
Description: C5-C6 and thoracic spine mobilization with postural correction
Study NCT06738485 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant single-chain factor VIII (rVIII-SingleChain)
Description: Lyophilized powder for solution for intravenous injection
Study NCT06734494 — intervention group
Intervention type: DEVICE
Intervention: Laparoscopic appendectomy Laparoscopic appendectomy with Airseal or with standard insufflation
Description: Airseal is a constant and low-pressure insufflation device. Standard insufflation is a variable pressure insufflation device.
Study NCT06725277 — intervention group
Intervention type: DRUG
Intervention: Spravato
Description: Intranasal esketamine
Study NCT06725277 — intervention group
Intervention type: DRUG
Intervention: IV Ketamine
Description: IV ketamine
Study NCT06741163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-activity shot
Description: Water-based shot containing olive leaf extract (100mg Oleuropein), vitamins, and other active ingredients. The product will be provided in sterilized Nalgene bottles of 60 mL, equivalent to one dose. Participants will consume one dose of the test product before their training session on each intervention day (Day 5, Day 6, and Day 7).
Study NCT06741163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water-based shot with similar appearance and taste but without the active ingredients of the test product. The placebo will be provided in sterilized Nalgene bottles of 60 mL, equivalent to one dose. Participants will consume one dose of the placebo before their training session on each intervention day (Day 5, Day 6, and Day 7).
Study NCT06734403 — intervention group
Intervention type: OTHER
Intervention: Bladder Augmentation
Description: Bladder Augmentation using bowel loop (ileal or sigmoid loop)
Study NCT06743126 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA203
Description: one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy
Study NCT06743126 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: nivolumab plus relatlimab
Description: in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
Study NCT06743126 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: lifileucel
Description: in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
Study NCT06743126 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: nivolumab
Description: in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
Study NCT06743126 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pembrolizumab
Description: in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
Study NCT05077449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Fulvestrant
Description: Placebo 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
Study NCT04405479 — intervention group
Intervention type: BEHAVIORAL
Intervention: Examination of tremor and upper hand functions
Description: Participants will be only examined. They will not undergo any intervention.
Study NCT05846282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STRIVE
Description: The STRIVE intervention will include all activities and BREATHE skill training components of L2B with content framed within the needs of high achieving college-bound BIPOC students who can benefit from health promoting practices to offset the costs of resilience. The intervention will include twelve 60-minute group sessions, with two sessions on each of the six core themes. Each session will include an opening mindful movement, short didactic presentation of the topic or theme of that week, group activities that illustrate the theme, guided discussion about the activity, and in-session group mindfulness meditation practice.
Study NCT05846282 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Study Skills
Description: The sessions will focus on goal setting (4 sessions), organization and time management (3 sessions), and study skills for reading comprehension, writing papers, note-taking, and test-taking (4 sessions). Parallel to the final L2B session, the last meeting will include activities to share and reflect on how students plan to incorporate and sustain new skills.
Study NCT05703360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual Stimulation
Description: The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit.~One or more of the spheres is temporarily highlighted (target). Then all 8 spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using the hand controller, the initially highlighted target(s) among the 8 spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased.~Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)
Study NCT05464186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole milk
Description: Weekly home delivery of whole milk, daily text messages, monthly virtual visits
Study NCT05464186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nonfat milk
Description: Weekly home delivery of nonfat milk, daily text messages, monthly virtual visits
Study NCT06377410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syrup Prospan
Description: Participant with stable COPD who received Syrup prospan for 1 month
Study NCT06377410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: Participant with stable COPD who received N-Acetylcysteine for 1 month
Study NCT05761652 — intervention group
Intervention type: OTHER
Intervention: Observe and record
Description: The general information, environmental indicators, and auxiliary examination indicators of the subjects were observed and recorded, as well as the TCM physical assessment was performed.
Study NCT05244720 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fibroscan
Description: A percutaneous scan, that measures shear wave velocity. It estimates liver stiffness.
Study NCT05244720 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fibroscan
Description: A percutaneous scan, that measures shear wave velocity. It estimates liver stiffness.
Study NCT05244720 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood samples
Description: Blood samples to asses the function of liver, kidney and bone marrow, as well as nutrition/vitamin status.
Study NCT05244720 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples to asses the function of liver, kidney and bone marrow, as well as nutrition/vitamin status.
Study NCT03703258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-based intervention
Description: A app-based cognitive-behavioral intervention to prevent the development of PTSD and high-risk drinking in recently-victimized adults